Centessa Pharmaceuticals PLC
NASDAQ:CNTA

Watchlist Manager
Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Watchlist
Price: 16.9 USD -3.59% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Centessa Pharmaceuticals PLC?
Write Note

Centessa Pharmaceuticals PLC
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Centessa Pharmaceuticals PLC
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash Taxes Paid
$2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash Taxes Paid
-ÂŁ29.2m
CAGR 3-Years
-92%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash Taxes Paid
$551k
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash Taxes Paid
$694k
CAGR 3-Years
98%
CAGR 5-Years
58%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash Taxes Paid
ÂŁ977k
CAGR 3-Years
N/A
CAGR 5-Years
69%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash Taxes Paid
ÂŁ21.5m
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
8%
No Stocks Found

Centessa Pharmaceuticals PLC
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

In the burgeoning landscape of biopharmaceutical innovation, Centessa Pharmaceuticals PLC stands out with a distinctive operating model that seeks to streamline the path from discovery to market. Centessa, founded in 2020, uniquely consolidates a range of biotech subsidiaries, each focused on distinct therapeutic areas. This structure enables them to maintain a sharp focus on scientific discovery while sharing corporate functions like operations, finance, and legal services to maximize efficiency. By integrating these companies under a single umbrella, Centessa hopes to mitigate the typical inefficiencies and bureaucratic delays that plague the path from pipeline to patient, driving forward their goal of developing transformative medicines. With an emphasis on nimblenes and productivity, Centessa monetizes its pipeline by advancing its most promising drug candidates through clinical development stages, subsequently seeking partnerships or acquisitions with larger pharmaceutical entities. The company's revenue stream hinges on the successful development and eventual commercialization or licensing of these pioneering therapies, often focusing on complex and challenging medical conditions. By nurturing a diverse portfolio of cutting-edge research programs — spanning areas like oncology, immunology, and rare diseases — Centessa strives to deliver breakthroughs that not only enhance patient lives but also provide substantial returns on investment through strategic collaborations and licensing deals within the pharmaceutical ecosystem.

CNTA Intrinsic Value
0.46 USD
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Centessa Pharmaceuticals PLC's Cash Taxes Paid?
Cash Taxes Paid
2.9m USD

Based on the financial report for Dec 31, 2023, Centessa Pharmaceuticals PLC's Cash Taxes Paid amounts to 2.9m USD.

What is Centessa Pharmaceuticals PLC's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 1Y
126%

Over the last year, the Cash Taxes Paid growth was 126%.

Back to Top